With regards to the clinicopathological significance of HIC1, our results found that HIC1 was expressed higher in patients with later clinical stages in BLCA, ESCA, and STAD, indicating that HIC1 may function as a biomarker for predicting disease progression for cancer patients. The gene discussed is HIC1; the disease is bladder transitional cell carcinoma.